<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40906343</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7322</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Heart failure reviews</Title><ISOAbbreviation>Heart Fail Rev</ISOAbbreviation></Journal><ArticleTitle>Cardiac resynchronization therapy in cancer patients with chemotherapy-induced cardiomyopathy: a mini review.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10741-025-10554-7</ELocationID><Abstract><AbstractText>Chemotherapy-induced cardiomyopathy (CHIC) represents a growing clinical challenge due to the increasing use of cardiotoxic treatments. These therapies can lead to progressive myocardial dysfunction, ultimately resulting in heart failure. Cardiac resynchronization therapy (CRT) has been widely investigated in selected patients with chronic heart failure; however, those with CHIC remain underrepresented in CRT trials. Current evidence is largely based on retrospective and observational studies, with MADIT-CHIC being the only prospective trial to date. No randomized controlled trials are currently available. Despite encouraging findings, existing data remain limited by small sample sizes and short follow-up durations. In particular, the impact of CRT on left ventricular dyssynchrony, arrhythmic burden, and long-term survival in this population has not been fully elucidated. A multidisciplinary cardio-oncology approach is essential not only for the comprehensive management of these complex patients, but also to guide appropriate timing of CRT implantation. Further research is warranted to refine patient selection criteria and to fully assess the long-term benefits and risks of CRT in patients with CHIC.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valzania</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8266-8407</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, IRCCS - Azienda Ospedaliero, Universitaria Di Bologna - Policlinico Di S. Orsola, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvi</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-7218-8781</Identifier><AffiliationInfo><Affiliation>Policlinico G. Rodolico - San Marco, Azienda Ospedaliera Universitaria, Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schirripa</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-1156-0113</Identifier><AffiliationInfo><Affiliation>Cardiology Unit, Pertini Hospital, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esposito</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><Identifier Source="ORCID">0009-0001-4014-547X</Identifier><AffiliationInfo><Affiliation>Cardiology Unit, San Giuseppe Moscati Hospital, Azienda Ospedaliera Di Rilievo Nazionale, Avellino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donnici</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiovascular Department, San Carlo Hospital, Azienda Ospedaliera Regionale, Potenza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borrello</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Cardiology and Intensive Care Unit, Pugliese-Ciaccio Hospital, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arestia</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Montevergine Clinic, Mercogliano, Avellino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sassone</LastName><ForeName>Biagio</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-9028-7169</Identifier><AffiliationInfo><Affiliation>Division of Provincial Cardiology, Department of Translational Medicine, University of Ferrara, Ferrara, Italy. biagio.sassone@unife.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Provincial Cardiology, Cardiothoracic Vascular Department, Azienda Unit&#xe0; Sanitaria Locale Di Ferrara, Ferrara, Italy. biagio.sassone@unife.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Task Force on Cardiac Resynchronization Therapy of the Italian Association of Arrhythmology and Cardiac Pacing (AIAC)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Heart Fail Rev</MedlineTA><NlmUniqueID>9612481</NlmUniqueID><ISSNLinking>1382-4147</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Cardiac resynchronization therapy</Keyword><Keyword MajorTopicYN="N">Cardiomyopathy</Keyword><Keyword MajorTopicYN="N">Chemotherapy</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors have no competing interests to declare that are relevant to the content of this article. The authors declare no competing interests. Conflicts of interest: Drs. C.V., V.C., V.S., F.E., G.D., F.B. and B.S. have no conflicts of interest or financial ties to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>4</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>4</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>4</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40906343</ArticleId><ArticleId IdType="doi">10.1007/s10741-025-10554-7</ArticleId><ArticleId IdType="pii">10.1007/s10741-025-10554-7</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Lyon AR, L&#xf3;pez-Fern&#xe1;ndez T, Couch LS et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43:4229&#x2013;4361. https://doi.org/10.1093/eurheartj/ehad196</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad196</ArticleId><ArticleId IdType="pubmed">36017568</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinale D, Colombo A, Bacchiani G et al (2015) Early detection of anthracycline cardiotoxicity and improvement with HF therapy. Circulation 131:1981&#x2013;1988. https://doi.org/10.1161/CIRCULATIONAHA.114.013777</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.114.013777</ArticleId><ArticleId IdType="pubmed">25948538</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869&#x2013;2879. https://doi.org/10.1002/cncr.11407</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.11407</ArticleId><ArticleId IdType="pubmed">12767102</ArticleId></ArticleIdList></Reference><Reference><Citation>Baech J, Hansen SM, Lund PE et al (2018) Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines. Br J Haematol 183:717&#x2013;726. https://doi.org/10.1111/bjh.16559</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16559</ArticleId><ArticleId IdType="pubmed">30406945</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowles EJ, Wellman R, Feigelson HS et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104:1293&#x2013;1305. https://doi.org/10.1093/jnci/djs317</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djs317</ArticleId><ArticleId IdType="pubmed">22949432</ArticleId><ArticleId IdType="pmc">3433392</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C, Maan A, Singh JP, Fradley MG (2021) Arrhythmias and device therapies in patients with cancer therapy-induced cardiomyopathy. Heart Rhythm 18:1223&#x2013;1229. https://doi.org/10.1016/j.hrthm.2021.02.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2021.02.017</ArticleId><ArticleId IdType="pubmed">33640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu HK, Yu W, Cheuk DK et al (2013) New three-dimensional speckle-tracking echocardiography identifies global impairment of left ventricular mechanics with a high sensitivity in childhood cancer survivors. J Am Soc Echocardiogr 26:846&#x2013;852. https://doi.org/10.1016/j.echo.2013.04.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2013.04.018</ArticleId><ArticleId IdType="pubmed">23727115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajijola OA, Nandigam KV, Chabner BA et al (2008) Usefulness of cardiac resynchronization therapy in the management of Doxorubicin-induced cardiomyopathy. Am J Cardiol 101:1371&#x2013;1372. https://doi.org/10.1016/j.amjcard.2007.12.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2007.12.037</ArticleId><ArticleId IdType="pubmed">18435975</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadol AP, Mouhayar E, Reyes-Gibby CC (2017) The use of cardiac resynchronization therapy in cancer patients with heart failure. J Clin Exp Res Cardiol 3. https://doi.org/10.15744/2394-6504.3.105</Citation></Reference><Reference><Citation>Shehram M, Khalid H, Shafique HM et al (2023) Efficacy and safety of cardiac resynchronization therapy in chemotherapy-induced cardiomyopathy: A systematic review. Ann Noninvasive Electrocardiol 28:e13070. https://doi.org/10.1111/anec.13070</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anec.13070</ArticleId><ArticleId IdType="pubmed">37435629</ArticleId><ArticleId IdType="pmc">10475884</ArticleId></ArticleIdList></Reference><Reference><Citation>Rickard J, Kumbhani DJ, Baranowski B et al (2010) Usefulness of cardiac resynchronization therapy in patients with Adriamycin-induced cardiomyopathy. Am J Cardiol 105:522&#x2013;526. https://doi.org/10.1016/j.amjcard.2009.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2009.10.024</ArticleId><ArticleId IdType="pubmed">20152248</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezzeddine FM, Saliba AN, Jain V et al (2021) Outcomes of cardiac resynchronization therapy in patients with chemotherapy-induced cardiomyopathy. Pacing Clin Electrophysiol 44:625&#x2013;632. https://doi.org/10.1111/pace.14196</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pace.14196</ArticleId><ArticleId IdType="pubmed">33592678</ArticleId><ArticleId IdType="pmc">8772340</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel D, Kumar A, Moennich LA et al (2022) Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy. Heart 108:274&#x2013;278. https://doi.org/10.1136/heartjnl-2020-318333</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2020-318333</ArticleId><ArticleId IdType="pubmed">34489312</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599&#x2013;3726. https://doi.org/10.1093/eurheartj/ehab368</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab368</ArticleId><ArticleId IdType="pubmed">34447992</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79:1757&#x2013;1780. https://doi.org/10.1161/CIR.0000000000001073</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001073</ArticleId><ArticleId IdType="pubmed">35379504</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JP, Solomon SD, Fradley MG et al (2019) Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With Chemotherapy-Induced Cardiomyopathy. JAMA 322:1799&#x2013;1805. https://doi.org/10.1001/jama.2019.16658</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.16658</ArticleId><ArticleId IdType="pubmed">31714987</ArticleId><ArticleId IdType="pmc">6865289</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss AJ, Hall WJ, Cannom DS et al (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 36:1329&#x2013;1338. https://doi.org/10.1056/NEJMoa0906431</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0906431</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazur M, Wang F, Hodge DO et al (2017) Burden of Cardiac Arrhythmias in Patients With Anthracycline-Related Cardiomyopathy. JACC Clin Electrophysiol 3:139&#x2013;150. https://doi.org/10.1016/j.jacep.2016.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacep.2016.08.009</ArticleId><ArticleId IdType="pubmed">29759386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghio S, Freemantle N, Scelsi L et al (2009) Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trialEur J. Heart Fail 11:480&#x2013;488. https://doi.org/10.1093/eurjhf/hfp034</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hfp034</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B, Wang Y, Tse G et al (2023) Radiotherapy-induced malfunctions of cardiac implantable electronic devices: A meta-analysis. Heart Rhythm 20(5):689&#x2013;698. https://doi.org/10.1016/j.hrthm.2023.01.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2023.01.024</ArticleId><ArticleId IdType="pubmed">36708909</ArticleId></ArticleIdList></Reference><Reference><Citation>Riccardi M, Pabon MA, Bhatt AS et al (2025) Heart Failure with Improved Ejection Fraction. Definitions, Epidemiology, and Management. J Am Coll Cardiol 85 (24):2401&#x2013;2015.&#xa0; https://doi.org/10.1016/j.jacc.2025.03.544</Citation></Reference><Reference><Citation>Kinoshita M, Kato S, Kodama S et al (2022) Native T1 heterogeneity for predicting reverse remodeling in patients with non-ischemic dilated cardiomyopathy. Heart Vessels 37(9):1541&#x2013;1550. https://doi.org/10.1007/s00380-022-02057-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00380-022-02057-4</ArticleId><ArticleId IdType="pubmed">35320392</ArticleId></ArticleIdList></Reference><Reference><Citation>Lup&#xf3;n J, Gaggin HK, de Antonio M et al (2015) Biomarker-assist score for reverse remodeling prediction in heart failure: the ST2-R2 score. Int J Cardiol 184:337&#x2013;343. https://doi.org/10.1016/j.ijcard.2015.02.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2015.02.019</ArticleId><ArticleId IdType="pubmed">25734941</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohebi R, Liu Y, Pi&#xf1;a IL et al (2022) Dose-response to sacubitril/valsartan in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 80(16):1529&#x2013;1541. https://doi.org/10.1016/j.jacc.2022.08.737</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.08.737</ArticleId><ArticleId IdType="pubmed">36229089</ArticleId></ArticleIdList></Reference><Reference><Citation>PareeK N, Cevallos J, Moliner P et al (2018) Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience. Eur J Heart Fail 20:1721&#x2013;1731. https://doi.org/10.1002/ejhf.1292</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.1292</ArticleId><ArticleId IdType="pubmed">30191649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom MW, Hamo CE, Cardinale D et al (2016) Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. Circ Heart Fail 9:e002661. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002661</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.115.002661</ArticleId><ArticleId IdType="pubmed">26747861</ArticleId><ArticleId IdType="pmc">4709035</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Wu Y, Zhang J (2021) Cardiac resynchronization therapy in heart failure patients: tough road but clear future. Heart Fail Rev 26:735&#x2013;745. https://doi.org/10.1007/s10741-020-10053-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-020-10053-x</ArticleId><ArticleId IdType="pubmed">33098491</ArticleId></ArticleIdList></Reference><Reference><Citation>Glikson M, Nielsen JC, Kronborg MB et al (2021) 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 42:3427&#x2013;3520. https://doi.org/10.1093/eurheartj/ehab364</Citation></Reference><Reference><Citation>Cho GY, Marwick TH, Kim HS et al (2009) Global 2-dimensional strain as a new prognosticator in patients with heart failure. J Am Coll Cardiol 54:618&#x2013;624.&#xa0; https://doi.org/10.1016/j.jacc.2009.04.061</Citation></Reference><Reference><Citation>D&#x2019;Andrea A, Caso P, Scarafile R et al (2009) Effects of global longitudinal strain and total scar burden on response to cardiac resynchronization therapy in patients with ischaemic dilated cardiomyopathy. Eur J Heart Fail 11:58&#x2013;67. https://doi.org/10.1093/eurjhf/hfn010</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjhf/hfn010</ArticleId><ArticleId IdType="pubmed">19147458</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahum J, Bensaid A, Dussault C et al (2010) Impact of longitudinal myocardial deformation on the prognosis of chronic heart failure patients. Circ Cardiovasc Imaging 3:249&#x2013;256. https://doi.org/10.1161/CIRCIMAGING.109.910893</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCIMAGING.109.910893</ArticleId><ArticleId IdType="pubmed">20233858</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan YH, Kuo CT, Wu LS et al (2016) Combined global longitudinal strain and intraventricular mechanical dyssynchrony predicts long-term outcome in patients with systolic heart failure. Circ J 80:177&#x2013;185. https://doi.org/10.1253/circj.CJ-15-0953</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>